Current Trends of Reproductive Immunology Practices in In Vitro fertilization (IVF) - A First World Survey Using IVF-Worldwide.com
Article first published online: 7 AUG 2012
© 2012 John Wiley & Sons A/S
American Journal of Reproductive Immunology
Volume 69, Issue 1, pages 12–20, January 2013
How to Cite
Citation Kwak-Kim J, Han AR, Gilman-Sachs A, Fishel S, Leong M, Shoham Z. Current trends of reproductive immunology practices in in vitro fertilization (IVF) - a first world survey using IVF-worldwide.com. Am J Reprod Immunol 2013; 69: 12–20
- Issue published online: 7 DEC 2012
- Article first published online: 7 AUG 2012
- Manuscript Accepted: 6 JUL 2012
- Manuscript Received: 1 JUL 2012
- IVF ;
- repeated implantation failure;
- recurrent pregnancy loss;
- reproductive immunology test;
- web-based survey
Reproductive immunology has evolved from basic research studies to clinical applications. In this study, we aim to investigate the actual application of reproductive immunology concepts and findings in clinical reproductive medicine such as recurrent pregnancy losses (RPL), repeated implantation failures (RIF), and failed in vitro fertilization (IVF) cycles.
Method of Study
A web-based survey was performed on IVF-Worldwide.com. Collected data were analyzed by the computerized software.
A significant proportion of physicians recommend thrombophilia workups (86%), parental genetic study (79%), and immunologic evaluations (69%) to IVF candidates who have a history of RPL or chemical pregnancy losses. IVF physicians consider an immunologic workup when patients have two (30%) or three (21%) failed IVF cycles. Assays for anticardiolipin antibody, lupus anticoagulant, thyroid peroxidase antibody, and antinuclear antibody are the four most commonly ordered immunologic tests for RPL (88, 84, 50, 47% each) and RIF (68, 63, 38, 38% each). Cellular immune evaluations, such as NK assay, human leukocyte antigen study, Th1/Th2 study or immunophenotype assay, are less commonly ordered.
Reproductive immunology principles have been applied to the clinical management of RPL, RIF, and failed IVF cycles, and a significant proportion of IVF physicians acknowledge the importance of immunologic alterations with reproductive outcomes.